Spatial‑omics firm Nucleai signed a collaboration with the University of Glasgow to identify and validate predictive biomarkers for colorectal cancer and advanced polyp risk using multimodal spatial biology and AI. The partners will analyze INCISE study data to map tissue architecture, cell‑cell interactions and molecular signaling tied to progression. The deal blends Nucleai’s AI‑driven tissue imaging with academic clinical datasets to develop diagnostics for personalized surveillance. The collaboration represents a step for Nucleai into diagnostics and reflects growing industry focus on spatial biology as a route to clinically actionable risk stratification.